Prostate Cancer Clinical Trial
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
Summary
This randomized phase II trial will evaluate if a low-fat diet with fish oil has the potential to delay disease progression in patients with prostate cancer undergoing active surveillance.
Full Description
PRIMARY OBJECTIVES:
I. Determine if a 1-year low-fat fish oil (omega-3 fatty acid) supplemented diet results in decreased prostate cancer Decipher score as compared to a control group in men on active surveillance.
SECONDARY OBJECTIVES:
I. Evaluate the effect of a low-fat (LF)/fish oil (FO) intervention on prostate biopsy tissue markers of progression, prostate biopsy pathologic features (Gleason grade, tumor volume ), prostate-specific antigen (PSA), and long-term clinical outcomes (clinical progression, prostate cancer therapies).
II. Evaluate potential surrogate biomarkers of proliferation (red blood cell [RBC] membrane fatty acid analyses, ex-vivo bioassay).
III. Determine if a correlation exists between free fatty acid receptor 4 (GPR120) levels and progression markers in response to the LF/FO intervention.
IV. Evaluate effect of the intervention on the National Comprehension Cancer Network (NCCN) risk group V. Evaluate compliance with a 1-year + 2 year extension LF/FO intervention. VI. Evaluate safety of a 1-year + 2-year extension LF/FO intervention.
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive no intervention.
ARM II: Patients receive dietary counseling with a research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a high omega-3, low omega-6 diet comprising 20% kilocalories (Kcal) from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day orally (PO) for 1 year.
After completion of study, patients are followed up yearly for 15 years.
Eligibility Criteria
Inclusion Criteria:
Patients sign the informed consent
Patient had a prostate biopsy performed by Dr. Mark with the Artemis device and has adenocarcinoma of the prostate
Patient elects to undergo active surveillance
Clinical stage T2c or less
Gleason grade 3+4 or less
PSA < 20
Geographically able to have study visits at the University of California, Los Angeles (UCLA) Clinical Research Unit
Subjects are willing to not consume lycopene, green tea or pomegranate supplements or pomegranate juice during the 1-year study
If subjects are randomized to the control group they agree to not consume fish oil capsules during the 1-year study
Exclusion Criteria:
Diagnostic prostate biopsy with only 1 core with cancer and < 5% of tissue from that core involved with cancer
Patient has taken finasteride or dutasteride during the prior year
Patient has taken fish oil during the prior 3 months
Patient had prior treatment for prostate cancer (surgery, radiation, local ablative therapy, anti-androgen therapy or androgen deprivation therapy)
Patient has other medical conditions that exclude him from undergoing a repeat prostate biopsy at 1-year
Patient has allergy to fish
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, 90095, United States
How clear is this clinincal trial information?